CD274 and neoplasm: As outlined in Table 3, the most highly cited study, conducted by Han Yao et al., titled “Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumors” (17), has been cited 79 times, highlighting its significant impact on tumor immunology and therapeutic strategies.